Immunovia Past Earnings Performance
Past criteria checks 0/6
Immunovia's earnings have been declining at an average annual rate of -22.7%, while the Medical Equipment industry saw earnings growing at 6.3% annually. Revenues have been growing at an average rate of 80.7% per year.
Key information
-22.7%
Earnings growth rate
-10.2%
EPS growth rate
| Medical Equipment Industry Growth | 6.2% |
| Revenue growth rate | 80.7% |
| Return on equity | -596.7% |
| Net Margin | -16,491.2% |
| Next Earnings Update | 22 Aug 2024 |
Recent past performance updates
Recent updates
Here's Why We're Watching Immunovia's (STO:IMMNOV) Cash Burn Situation
Apr 20
We're Keeping An Eye On Immunovia's (STO:IMMNOV) Cash Burn Rate
Dec 09Is Immunovia (STO:IMMNOV) In A Good Position To Invest In Growth?
May 13Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation
Jan 18We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth
Aug 28What Kind Of Investors Own Most Of Immunovia AB (publ) (STO:IMMNOV)?
Mar 09Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation
Feb 03
Immunovia AB (publ)'s (STO:IMMNOV) Intrinsic Value Is Potentially 72% Above Its Share Price
Dec 30Insider Buying: The Immunovia AB (publ) (STO:IMMNOV) Director Just Bought kr293k Worth Of Shares
Dec 03Revenue & Expenses BreakdownBeta
How Immunovia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2 | -261 | 128 | 0 |
| 31 Dec 23 | 2 | -309 | 148 | 0 |
| 30 Sep 23 | 2 | -328 | 173 | 0 |
| 30 Jun 23 | 2 | -312 | 171 | 0 |
| 31 Mar 23 | 1 | -176 | 165 | 0 |
| 31 Dec 22 | 1 | -168 | 163 | 0 |
| 30 Sep 22 | 1 | -148 | 162 | 0 |
| 30 Jun 22 | 1 | -161 | 158 | 0 |
| 31 Mar 22 | 1 | -177 | 165 | 0 |
| 31 Dec 21 | 1 | -156 | 162 | 0 |
| 30 Sep 21 | 1 | -155 | 165 | 0 |
| 30 Jun 21 | 0 | -157 | 175 | 0 |
| 31 Mar 21 | 0 | -142 | 161 | 0 |
| 31 Dec 20 | 0 | -146 | 165 | 0 |
| 30 Sep 20 | 0 | -133 | 213 | 0 |
| 30 Jun 20 | 0 | -120 | 184 | 0 |
| 31 Mar 20 | 0 | -116 | 162 | 0 |
| 31 Dec 19 | 0 | -115 | 133 | 0 |
| 30 Sep 19 | -19 | -108 | 52 | 0 |
| 30 Jun 19 | -13 | -99 | 51 | 0 |
| 31 Mar 19 | -6 | -96 | 48 | 0 |
| 31 Dec 18 | 0 | -87 | 45 | 0 |
| 30 Sep 18 | 29 | -76 | 46 | 0 |
| 30 Jun 18 | 26 | -70 | 38 | 0 |
| 31 Mar 18 | 25 | -55 | 34 | 0 |
| 31 Dec 17 | 24 | -45 | 31 | 0 |
| 30 Sep 17 | 23 | -35 | 24 | 0 |
| 30 Jun 17 | 24 | -28 | 23 | 0 |
| 31 Mar 17 | 25 | -20 | 19 | 0 |
| 31 Dec 16 | 24 | -15 | 16 | 0 |
| 30 Sep 16 | 22 | -11 | 12 | 0 |
| 30 Jun 16 | 22 | -9 | 11 | 0 |
| 31 Mar 16 | 19 | -8 | 9 | 0 |
| 31 Dec 15 | 17 | -7 | 7 | 0 |
| 30 Sep 15 | 12 | -9 | 5 | 0 |
| 30 Jun 15 | 7 | -10 | 4 | 0 |
| 31 Mar 15 | 4 | -9 | 3 | 0 |
| 31 Dec 14 | 0 | -9 | 2 | 0 |
| 31 Dec 13 | 1 | -2 | 1 | 0 |
Quality Earnings: IMMNOV is currently unprofitable.
Growing Profit Margin: IMMNOV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMMNOV is unprofitable, and losses have increased over the past 5 years at a rate of 22.7% per year.
Accelerating Growth: Unable to compare IMMNOV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMMNOV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (59.4%).
Return on Equity
High ROE: IMMNOV has a negative Return on Equity (-596.7%), as it is currently unprofitable.